1.58 USD
+0.04
2.60%
At close Apr 25, 4:00 PM EDT
Pre-market
1.58
+0.00
0.00%
1 day
2.60%
5 days
8.97%
1 month
-16.84%
3 months
-28.83%
6 months
-9.71%
Year to date
-18.97%
1 year
-27.52%
5 years
-16.84%
10 years
-82.44%
 

About: Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Employees: 987

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

913% more call options, than puts

Call options by funds: $162K | Put options by funds: $16K

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

9% more capital invested

Capital invested by funds: $99.5M [Q3] → $108M (+$8.97M) [Q4]

5% more funds holding

Funds holding: 126 [Q3] → 132 (+6) [Q4]

8% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 40

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0.64% less ownership

Funds ownership: 55.12% [Q3] → 54.48% (-0.64%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ARAY.

Financial journalist opinion

Positive
Zacks Investment Research
2 weeks ago
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Neutral
PRNewsWire
3 weeks ago
Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis. , April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife ® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors.
Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting
Neutral
PRNewsWire
1 month ago
Accuray to Participate at 37th Annual Roth Conference
MADISON, Wis. , March 12, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in the 37th Annual Roth Conference taking place on March 16 -18, 2025 in Dana Point, California.
Accuray to Participate at 37th Annual Roth Conference
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Positive
Zacks Investment Research
2 months ago
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
Accuray delivers solid fiscal second-quarter results, witnessing growth in Product revenues and reduced operating expenses.
ARAY Stock Up as Q2 Earnings & Revenues Beat Estimates, Margins Up
Neutral
Seeking Alpha
2 months ago
Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript
Accuray Incorporated (NASDAQ:ARAY ) Q2 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Operator Good day, and welcome to the Accuray Fiscal 2025 Second Quarter Financial Results Conference Call. All participants will be in a listen-only mode.
Accuray Incorporated (ARAY) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
Zacks Investment Research
2 months ago
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago.
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
Neutral
PRNewsWire
2 months ago
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024.
Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance
Neutral
PRNewsWire
3 months ago
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
MADISON, Wis. , Jan. 23, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Shandong Cancer Hospital and Institute has achieved a milestone with the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture.
Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product
Charts implemented using Lightweight Charts™